Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster … 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
COVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use … 02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens … 01/06/22 Health Advisory: Booster Eligibility Expanded
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and … 01/04/22 Health Advisory: CDC updated antiviral guidance
To report a confirmed or suspect case of pertussis, complete the or call . Overview Pertussis is common and very contagious. It is caused by Bordetella pertussis. The bacteria infect cilia in the upper respiratory tract. Early symptoms are mild, like the common cold. Patients often experience violent coughing fits (paroxysms). These can be followed by … Pertussis Fact Sheet
Overview Transmission: Fecal-oral. Incubation Period: Average 28-30 days (range 15-50 days). Symptoms: Anorexia, vomiting, abdominal pain, fatigue, followed by jaundice. Severity of illness increases with age. Infectious Period: 14 days prior to onset of jaundice to seven days after onset of jaundice. Infants can excrete virus in the stool for longer periods of time. Epidemiology: … Hepatitis A Fact Sheet
Action Requested Know how to order appropriate Zika virus testing through commercial laboratories. Background Because testing for Zika virus is now widely available through commercial laboratories, testing for Zika virus at Washington State Public Health Laboratories is now limited to: Patients for whom cost is a barrier to testing. Infants with possible congenital exposure to … Health Advisory: Zika Testing
What is hand hygiene? Hand hygiene refers to the use of hand washing with soap and water or alcohol hand sanitizer (60% alcohol or greater) in order to reduce infection rates, reduce transmission of antimicrobial resistant organisms and stop outbreaks of communicable disease. Why is hand hygiene important? When should I use hand hygiene? How … Hand Hygiene In Healthcare Settings
